Harold J Burstein MD PhD and Lisa A Carey MD on Innovations in Triple Neg BC

Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH

Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH, on the Movement Toward Bilateral Surgical Procedures

Ismail Jatoi, MD, PhD, FACS, of the University of Texas Health Science Center and Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute discuss the increasing movement away from breast conservation toward bilateral surgical procedures.

Breast Cancer

Hope S. Rugo, MD

Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer

Jame Abraham, MD, FACP, of the Cleveland Clinic, offers his thoughts on abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

Related Videos

Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH, on the Movement Toward Bilateral Surgical Procedures

Hope S. Rugo, MD, on the Phase II FIRST Study

Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial

Charles E. Geyer, Jr, MD, FACP, on the SOFT Trial

Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer

Radiopharmaceutical Therapy May Offer Benefit in Patients With Refractory Meningioma

Spiritual Themes Distrust May Factor Into Black Patients Reluctance to Participate in Cancer Clinical Trials

NO-CUT Trial: Nonoperative Management of Benefit for Many Patients With Rectal Cancer

Novel Radioconjugate or Conventional Care Prior to Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory AML

Atezolizumab Plus Platinum Doublet and Maintenance Niraparib for Late-Relapsing Recurrent Ovarian Cancer